Intact Investment Management Inc. Acquires 6,680 Shares of Becton, Dickinson and Company (NYSE:BDX)

Intact Investment Management Inc. raised its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 42.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 22,350 shares of the medical instruments supplier’s stock after purchasing an additional 6,680 shares during the period. Intact Investment Management Inc.’s holdings in Becton, Dickinson and Company were worth $5,389,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Old North State Wealth Management LLC grew its stake in shares of Becton, Dickinson and Company by 4.2% during the 3rd quarter. Old North State Wealth Management LLC now owns 19,642 shares of the medical instruments supplier’s stock valued at $4,744,000 after acquiring an additional 786 shares during the period. Forum Financial Management LP lifted its holdings in Becton, Dickinson and Company by 39.0% during the third quarter. Forum Financial Management LP now owns 2,467 shares of the medical instruments supplier’s stock valued at $595,000 after purchasing an additional 692 shares in the last quarter. Robeco Institutional Asset Management B.V. lifted its holdings in Becton, Dickinson and Company by 62.0% during the third quarter. Robeco Institutional Asset Management B.V. now owns 42,013 shares of the medical instruments supplier’s stock valued at $10,129,000 after purchasing an additional 16,074 shares in the last quarter. Veritas Asset Management LLP raised its position in shares of Becton, Dickinson and Company by 9.0% during the 3rd quarter. Veritas Asset Management LLP now owns 2,295,205 shares of the medical instruments supplier’s stock valued at $553,374,000 after purchasing an additional 189,520 shares during the period. Finally, Fort L.P. purchased a new position in shares of Becton, Dickinson and Company during the 3rd quarter valued at $226,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.4 %

Shares of NYSE:BDX opened at $234.33 on Tuesday. The business’s 50-day moving average is $237.52 and its 200 day moving average is $235.10. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $259.92. The firm has a market capitalization of $67.73 billion, a P/E ratio of 48.22, a P/E/G ratio of 1.75 and a beta of 0.43.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on BDX shares. Evercore ISI raised their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Stifel Nicolaus upped their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Raymond James dropped their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Finally, Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price target for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, Becton, Dickinson and Company currently has an average rating of “Buy” and a consensus target price of $282.63.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.